Rani Net Income Applicable To Common Shares from 2010 to 2026
| RANI Stock | USD 1.27 0.05 4.10% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -55.1 M | Current Value -52.3 M | Quarterly Volatility 16.8 M |
Check Rani Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rani Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 1.3 M, Depreciation And Amortization of 742.1 K or Interest Expense of 6.1 M, as well as many indicators such as Price To Sales Ratio of 41.46, Dividend Yield of 0.0 or PTB Ratio of 18.51. Rani financial statements analysis is a perfect complement when working with Rani Therapeutics Valuation or Volatility modules.
Rani | Net Income Applicable To Common Shares | Build AI portfolio with Rani Stock |
The Net Income Applicable To Common Shares trend for Rani Therapeutics Holdings offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Rani Therapeutics is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Rani Therapeutics' Net Income Applicable To Common Shares Growth Pattern
Below is the plot of the Net Income Applicable To Common Shares of Rani Therapeutics Holdings over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Rani Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rani Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income Applicable To Common Shares | 10 Years Trend |
|
Net Income Applicable To Common Shares |
| Timeline |
Rani Net Income Applicable To Common Shares Regression Statistics
| Arithmetic Mean | (34,223,287) | |
| Coefficient Of Variation | (49.01) | |
| Mean Deviation | 14,091,229 | |
| Median | (26,587,000) | |
| Standard Deviation | 16,772,212 | |
| Sample Variance | 281.3T | |
| Range | 52.8M | |
| R-Value | (0.63) | |
| Mean Square Error | 182.2T | |
| R-Squared | 0.39 | |
| Significance | 0.01 | |
| Slope | (2,081,732) | |
| Total Sum of Squares | 4500.9T |
Rani Net Income Applicable To Common Shares History
About Rani Therapeutics Financial Statements
Investors use fundamental indicators, such as Rani Therapeutics' Net Income Applicable To Common Shares, to determine how well the company is positioned to perform in the future. Although Rani Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Net Loss | -55.1 M | -52.3 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Rani Therapeutics Correlation against competitors. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is there potential for Biotechnology market expansion? Will Rani introduce new products? Factors like these will boost the valuation of Rani Therapeutics. Anticipated expansion of Rani directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Rani Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.77) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Understanding Rani Therapeutics requires distinguishing between market price and book value, where the latter reflects Rani's accounting equity. The concept of intrinsic value - what Rani Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Rani Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Rani Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rani Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Rani Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.